75835-01-7Relevant articles and documents
Solvent-free alkylation of N-heteroaromatic compounds by RCOOH-Pb(OAc) 4 system
Nikishin,Sokova,Makhaev,Kapustina
, p. 997 - 1002 (2005)
The solvent-free decarboxylation of carboxylic acids by Pb(OAc)4 affords alkyl radicals, which alkylate 4-methylpyridine, quinoline, and 4-methylquinoline protonated with 2-chlorobenzoic acid. Mechanical activation is required for pyrazine alky
Ruthenium-catalyzed conversion of sp3 C-O bonds in ethers to C-C bonds using triarylboroxines
Ogiwara, Yohei,Kochi, Takuya,Kakiuchi, Fumitoshi
, p. 3254 - 3257 (2011/08/02)
Catalytic conversion of unreactive sp3 C-O bonds in alkyl ethers to C-C bonds is described. Alkyl ethers bearing 2- or 4-pyridyl groups were coupled with triarylboroxines in the presence of a ruthenium catalyst. Triarylboroxines bearing a variety of functional groups including electron-withdrawing and -donating groups can be used for the reaction. No additional base was required for the coupling with the organoboron reagents, and base-sensitive groups can be tolerated. The reaction is considered to proceed via dehydroalkoxylation followed by addition of triarylboroxines to form C-C bonds.
ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
-
Page/Page column 69, (2009/06/27)
The present invention relates to compounds defined by formula (I), wherein the groups R1 to R3, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.
